Speakers 2016

    • Presentation

    • NORTH & WEST (chairman)

    View more
  • ASSELAH Tarik

    France

      Presentation

    • State of the art lecture (chairman)

    • How to improve the therapeutic strategies?

    • Can we expect eradication in HCV G4?

    View more
  • BEDOSSA Pierre

    France

      Presentation

    • Staging of steatosis and fibrosis: liver biopsy or indirect markers? (chairman)

    View more
  • BELHADJ BRIK Najet

    Tunisia

      Presentation

    • HCV : comment re-traiter les rechuteurs et les non-répondeurs ? (French speaking lunch workshop)

    View more
  • BENAZZOUZ Mustapha

    Morocco

      Presentation

    • Traitements des patients atteints de cirrhose (French speaking lunch workshop)

    View more
    • Presentation

    • How to optimize therapy? (chairman)

    • New therapeutic strategies (chairman)

    • State of the art lecture (chairman)

    • How to optimize treatment in G3 patients? (chairman)

    • Take home message

    View more
  • BRONOWICKI Jean-Pierre

    France

      Presentation

    • Traitements des patients atteints de cirrhose (French speaking lunch workshop) (chairman)

    View more
    • Presentation

    • Is the benefit to treat patients with cirrhosis proven?

    View more
  • BUTI Maria

    Spain

      Presentation

    • Special populations (chairman)

    View more
  • CADRANEL Jean-François David

    France

      Presentation

    • HBV : Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop) (chairman)

    View more
  • CASTERA Laurent

    France

      Presentation

    • Staging of steatosis and fibrosis: liver biopsy or indirect markers?

    • What's new in hepatitis B? (chairman)

    View more
  • COLOMBO Massimo

    Italy

      Presentation

    • NORTH & WEST (chairman)

    • Take home messages

    • How to optimize treatment in G3 patients?

    • Treatment of hepatocellular carcinoma: beyond international guidelines

    View more
  • CRAXI Antonio

    Italy

      Presentation

    • Who to treat? (chairman)

    • Why do I treat my patients with mild hepatitis?

    • Clinical applications of HBsAg quantification

    View more
  • DE LEDINGHEN Victor

    France

      Presentation

    • NORTH & WEST

    • Staging of steatosis and fibrosis: liver biopsy or indirect markers? (chairman)

    View more
  • DEBZI Nabil

    Algeria

      Presentation

    • Traitement HBV : Interféron ou analogues? (French speaking lunch workshop)

    View more
  • DHUMEAUX Daniel

    France

      Presentation

    • HCV : comment re-traiter les rechuteurs et les non-répondeurs ? (French speaking lunch workshop) (chairman)

    View more
  • DI BISCEGLIE Adrian

    USA

      Presentation

    • How to manage relapsers and non-responders to PEG-IFN + RBV therapy? (chairman)

    • End-stage liver disease is a multifaceted condition (chairman)

    View more
  • DI MARTINO Vincent

    France

      Presentation

    • Are DAAs therapies associated with HCV eradication?

    View more
  • DURAND François

    France

      Presentation

    • Treatment of HCV cirrhosis and transplanted patients: when and how?

    • Special populations (chairman)

    View more
  • El RAY Ahmed

    Egypt

      Presentation

    • SOUTH & EAST

    View more
  • ESMAT Gamal

    Egypt

      Presentation

    • Can we expect eradication in HCV G4? (chairman)

    View more
  • ESTEBAN Rafael

    Spain

      Presentation

    • NORTH & WEST

    View more
  • ESTRABAUD Emilie

    France

      Presentation

    • Are DAAs therapies associated with HCV eradication?

    View more
  • FERENCI Peter

    Austria

      Presentation

    • How to optimize the strategy against HCV? (chairman)

    • How to manage relapsers and non-responders to PEG-IFN + RBV therapy? (chairman)

    View more
  • FLISIAK Robert

    Poland

      Presentation

    • SOUTH & EAST (chairman)

    • Need to assess HCV resistance profile before the initiation of DAAs therapy?

    View more
  • FOSTER Graham

    UK

      Presentation

    • Individual optimization of therapy (shorten therapy)

    • NORTH & WEST

    • First line therapy of hepatitis B: interferon or analogues? (chairman)

    View more
  • FRANCOZ Claire

    France

      Presentation

    • Traitements des patients atteints de cirrhose (French speaking lunch workshop)

    View more
    • Presentation

    • The influence of therapy on the burden of hepatitis C

    • How to optimize treatment in G3 patients? (chairman)

    View more
    • Presentation

    • SOUTH & EAST (chairman)

    • Future therapies for HBV and HDV: what can we expect?

    • Optimal therapy of chronic hepatitis B (chairman)

    View more
  • GINES Pere

    Spain

      Presentation

    • Management of uninfected and infected ascites in cirrhosis

    View more
  • GOURNAY Jérôme

    France

      Presentation

    • How to optimize treatment in G3 patients?

    View more
  • HALFON Philippe

    France

      Presentation

    • Clinical applications of HBsAg quantification (chairman)

    View more
  • HEZODE Christophe

    France

      Presentation

    • Why don’t I treat my patients with mild hepatitis?

    • Need to assess HCV resistance profile before the initiation of DAAs therapy?

    View more
  • HORBAN Andrzej

    Poland

      Presentation

    • How to manage relapsers and non-responders to PEG-IFN + RBV therapy?

    View more
  • ISAKOV Vasily

    Russia

      Presentation

    • SOUTH & EAST

    View more
  • JIA Jidong

    China

      Presentation

    • Clinical applications of HBsAg quantification (chairman)

    • Optimal therapy of chronic hepatitis B (chairman)

    • Which pregnant women to treat?

    View more
  • KAO Jia-Horng

    Taiwan

      Presentation

    • First line therapy of hepatitis B: interferon or analogues? (chairman)

    • New therapeutic perspectives?

    View more
  • LAMPERTICO Pietro

    Italy

      Presentation

    • Prognosis and management of inactive carriers

    View more
  • LEROY Vincent

    France

      Presentation

    • HCV : comment re-traiter les rechuteurs et les non-répondeurs ? (French speaking lunch workshop)

    View more
  • LEVRERO Massimo

    France

      Presentation

    • Future therapies for HBV and HDV: what can we expect?

    View more
    • Presentation

    • How to optimize therapy? (chairman)

    • Future therapies for HBV and HDV: what can we expect? (chairman)

    View more
  • MANNS Michael

    Germany

      Presentation

    • NORTH & WEST

    • Future therapies for HBV and HDV: what can we expect? (chairman)

    • New therapeutic strategies (chairman)

    View more
  • MARCELLIN Patrick

    France

      Presentation

    • Introduction: Treatment of hepatitis C: Access to eradication !

    • Conclusion

    • Introduction: Hepatitis B, the come back?

    • State of the art lecture and award (chairman)

    • Conclusion

    View more
  • MARTINOT-PEIGNOUX Michelle

    France

      Presentation

    • Virological markers for the management of patients

    View more
  • MATHURIN Philippe

    France

      Presentation

    • First line therapy of hepatitis B: interferon or analogues?

    • HCV : comment re-traiter les rechuteurs et les non-répondeurs ? (French speaking lunch workshop) (chairman)

    View more
  • MOREAU Richard

    France

      Presentation

    • End-stage liver disease is a multifaceted condition (chairman)

    View more
  • MOUCARI Rami

    United Arab Emirates

      Presentation

    • Clinical applications of HBsAg quantification

    View more
    • Presentation

    • How to provide the best treat with what is available?

    View more
  • OUZAN Denis

    France

      Presentation

    • HBV : Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop) (chairman)

    View more
  • PAGEAUX Georges-Philippe

    France

      Presentation

    • Treatment of HCV cirrhosis and transplanted patients: when and how?

    View more
  • PAIS Raluca

    France

      Presentation

    • Management and treatment of NASH

    View more
  • PAPATHEODORIDIS Georgios

    Greece

      Presentation

    • First line therapy of hepatitis B: interferon or analogues?

    • Do I treat my immunotolerant patients?

    View more
  • PARANA Raymundo

    Brazil

      Presentation

    • SOUTH & EAST

    View more
  • PÉRON Jean-Marie

    France

      Presentation

    • Hepatitis E : the neglected one

    View more
  • PIETRANGELO Antonello

    Italy

      Presentation

    • Management and treatment of NASH (chairman)

    • Iron and the liver

    View more
  • POL Stanislas

    France

      Presentation

    • Who to treat? (chairman)

    • HIV-HCV coinfections (chairman)

    • Patients with chronic Kidney diseases

    View more
  • POPESCU Adriana

    Romania

      Presentation

    • HBV : Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop)

    View more
  • RATZIU Vlad

    France

      Presentation

    • Management and treatment of NASH (chairman)

    View more
  • RIZZETTO Mario

    Italy

      Presentation

    • The adventure of Delta

    View more
  • SALMON Dominique

    France

      Presentation

    • HIV-HCV coinfections

    View more
  • SAMUEL Didier

    France

      Presentation

    • Treatment of HCV cirrhosis and transplanted patients: when and how? (chairman)

    • DAAs and transplanted patients

    View more
  • SCHIFF Eugene

    USA

      Presentation

    • How to optimize the strategy against HCV? (chairman)

    View more
  • SERFATY Lawrence

    France

      Presentation

    • Follow-up of patients with SVR

    • Are DAAs therapies associated with HCV eradication? (chairman)

    View more
  • SHIFFMAN Mitchell

    USA

      Presentation

    • Universal screening?

    • Are DAAs therapies associated with HCV eradication? (chairman)

    View more
  • SOGNI Philippe

    France

      Presentation

    • Traitement HBV : Interféron ou analogues? (French speaking lunch workshop)

    View more
  • SULKOWSKI Mark

    USA

      Presentation

    • HIV-HCV coinfections (chairman)

    • HIV-HCV co-infected patients

    View more
  • TRAN Albert

    France

      Presentation

    • HBV : Faut-il traiter les immunotolérants et les porteurs inactifs ? (French speaking lunch workshop)

    View more
  • TREPO Christian

    France

      Presentation

    • Traitement HBV : Interféron ou analogues? (French speaking lunch workshop) (chairman)

    View more
  • TSERTSVADZE Tengiz

    Georgia

      Presentation

    • SOUTH & EAST

    View more
  • URBANEK Petr

    Czech Republic

      Presentation

    • Management and treatment of NASH

    View more
  • VALLA Dominique

    France

      Presentation

    • Treatment of HCV cirrhosis and transplanted patients: when and how? (chairman)

    View more
  • VOICULESCU Mihai

    Romania

      Presentation

    • SOUTH & EAST

    • Traitements des patients atteints de cirrhose (French speaking lunch workshop) (chairman)

    View more
  • WAKED Imam

    Egypt

      Presentation

    • Can we expect eradication in HCV G4?

    View more
  • YAZDANPANAH Yazdan

    France

      Presentation

    • HIV-HCV coinfections

    View more
  • ZARSKI Jean-Pierre

    France

      Presentation

    • Traitement HBV : Interféron ou analogues? (French speaking lunch workshop) (chairman)

    View more
  • ZEUZEM Stefan

    Germany

      Presentation

    • Is it useful to detect resistance associated variants?

    View more
  • ZHDANOV Konstantin

    Russia

      Presentation

    • How to manage relapsers and non-responders to PEG-IFN + RBV therapy?

    View more
  • ZOULIM Fabien

    France

      Presentation

    • What's new in hepatitis B? (chairman)

    • Clinical relevance of HBV cccDNA

    • Need to assess HCV resistance profile before the initiation of DAAs therapy? (chairman)

    View more